Table 4 Long-term follow up data
Variables | Patients with technical success (n = 214) |
|---|---|
Primary efficacy endpoint | 26 (12.15%) |
 Stroke/TIA | 19 (8.88%) |
 Systemic embolism | 2 (0.93%) |
 Death from cardiovascular causes | 7 (3.27%)* |
Severe bleeding events | 5 (2.34%) |
 Cerebral hemorrhage, n (%) | 0 (0) |
 Gastrointestinal bleeding, n (%) | 3 (1.40%) |
 Other major bleeding, n (%) | 2 (0.93%) |
Minor bleeding events, n (%) | 4 (1.87%) |
Non-cardiovascular death, n (%) | 15 (7.01%) |
All-cause death, n (%) | 19 (8.88%) |
PDL > 5 mm, n (%) | 1 (0.47%) |
DRT, n (%) | 5 (2.33%) |